Comparison between a Human Small Cell Lung Carcinoma Cell Line (GLC4) and an Adriamycin (GLC4-ADR) and a CDDP (GLC4-CDDP) Resistant Subline. A Preliminary Report

  • G. A. P. Hospers
  • N. H. Mulder
  • B. De Jong
  • J. G. Zijlstra
  • E. G. E. De Vries
Part of the Developments in Oncology book series (DION, volume 54)


Many relatively effective strategies for treatment of nearly all forms of chemosensitive cancer include combinations or alternations of agents that are supposed to have different modes of actions. In part these strategies are based on the assumption that such differing modes of action will ensure that tumor cells that are not sensitive to one agent will react to the other. This assumption requires that a close relation exists between mode of action of a drug and the mechanism of resistance operating for that drug in tumor cells. We have studied this hypothesis for two drugs that are considered to be active cytotoxic agents in a number of human malignancies, including small cell lung cancer, namely Adriamycin (ADR) and CDDP. This preliminary report concerns some details on the pheno- and genotype, and resistance mechanisms of a platinum (GLC4-CDDP) and of an ADR resistant (GLC4-ADR) and a CDDP resistant (GLC4-CDDP) cell line, both derived from a sensitive human small cell lung cancer cell line (GLC4).


Small Cell Lung Cancer Clonogenic Assay Small Cell Lung Cancer Cell Cell Lung Cancer Cell Line Sulfhydryl Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Vries, E.G.E., Meyer, C., Mulder, N.H. and Postmus, P.E. Eur.J.Cancer Clin.Oncol. 23: 55–60, 1987.CrossRefGoogle Scholar
  2. 2.
    Bachur, N.R., Moore, A.L., Bernstein, J.G. and Liu, A. Cancer Chemother. Rep. 54: 89–94, 1970.PubMedGoogle Scholar
  3. 3.
    Meyer, C, Mulder, N.H., Timmer-Bosscha, H., Zijlstra, J.G. and de Vries, E.G.E. Cancer Res. in press.Google Scholar
  4. 4.
    Lowry, O.H., Rosebroug, N.J., Farr, A.L. and Randall, R.J. J.Biol.Chem. 193: 265–275, 1951.PubMedGoogle Scholar
  5. 5.
    Birnboim, H.C. and Jevcah, J.J. Cancer Res. 41: 1889–1892, 1981.PubMedGoogle Scholar
  6. 6.
    De Jong, S., Zijlstra, J.G., Timmer-Bosscha, H., Mulder, N.H. and de Vries, E.G.E. Int.J.Cancer 37: 557–561, 1986.CrossRefGoogle Scholar
  7. 7.
    Carney, D.N., Gazdar, A.F., Nau, M, and Minna, J.D. Sem.Oncol. 12: 289–303, 1985.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • G. A. P. Hospers
  • N. H. Mulder
  • B. De Jong
  • J. G. Zijlstra
  • E. G. E. De Vries

There are no affiliations available

Personalised recommendations